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ABSTRACT 
 
Objectives: To estimate the risk of miscarriage after amniocentesis or chorionic villus 
sampling (CVS) based on a systematic review of the literature. 
Methods: A search of MEDLINE, EMBASE, and The Cochrane Library (2000-2017) 
was carried out to identify studies reporting complications following CVS or 
amniocentesis. The inclusion criteria for the systematic review were studies reporting 
results from large controlled studies (n1,000 invasive procedures) and those reporting 
data for pregnancy loss prior to 24 weeks’ gestation. Data for cases that had invasive 
procedure and controls were inputted in contingency tables and risk of miscarriage was 
estimated for each study. Summary statistics were calculated after taking into account 
the weighting for each study included in the systematic review. Procedure-related risk 
of miscarriage was estimated as a weighted risk difference from the summary statistics 
for cases and controls.  
Results: The electronic search from the databases yielded 2,465 potential citations of 
which 2,431 were excluded, leaving 34 studies for full-text review. The final review 
included 10 studies for amniocentesis and 6 studies for CVS, which were used to 
estimate risk of miscarriage in pregnancies that had an invasive procedure and the 
control pregnancies that did not. The procedure-related risk of miscarriage following 
amniocentesis was 0.35% (95% confidence interval [CI]: 0.07 to 0.63) and that 
following CVS was 0.35% (95%C CI:  -0.31 to 1.00). 
Conclusion: The procedure-related risks of miscarriage following amniocentesis and 
CVS are lower than currently quoted to women. 
 
Introduction 
Amniocentesis and chorionic villus sampling (CVS) are procedures used commonly for 
prenatal diagnosis. It is essential that women are given accurate information regarding 
risk of miscarriage from invasive procedures carried out by Fetal Medicine experts in 
experienced centres who routinely perform them. There is however inconsistency in the 
information from professional bodies which state that the risk following amniocentesis 
is about 1% whereas that following CVS is about 1-2%.1-5 This contrasts with evidence 
from recent studies which report a significantly lower rate of procedure-related risks 
following amniocentesis and CVS.6,7 A meta-analysis of large controlled studies 
reporting results from 324 losses in 42,176 women who underwent amniocentesis and 
207 losses in 8,899 women who underwent CVS stated that the procedure-related risks 
is about 0.1% and 0.2%, respectively.6 Another large nationwide population-based 
study of 147,987 women with a singleton pregnancy including 5,072 who underwent 
CVS and 1,809 who underwent amniocentesis, reported that the procedure-related risk 
of miscarriage at 21 days following CVS was -0.21% and that at 28 days following 
amniocentesis was 0.56%.7 It is important to standardise information provided to 
women especially in light of recent changes in clinical practice with the introduction of 
cell-free DNA (cfDNA) testing so that when women are faced with a high-risk result, 
they make choices about risks and benefits based on up-to-date evidence rather than 
basing decisions on historical figures. 
 
The objective of this study was to estimate the procedure-related risks of miscarriage 
following amniocentesis and CVS from a systematic review of literature. 
 
Methods 
 
Data sources and search strategy 
An electronic search of MEDLINE, EMBASE, and The Cochrane Library including The 
Cochrane Database of Systematic Reviews (CDSR) was carried out on 30th September 
2017 utilising combinations of the relevant Medical Subject Heading (MeSH) terms, key 
words, and word variants for “Amniocentesis”, ”Chorionic Villus Sampling (CVS)”, 
“miscarriage”, “pregnancy loss” and “procedure-related risk”. The search and selection 
criteria were restricted to studies reported in English language. The citations retrieved 
following this search strategy were examined for relevance to this study based on the 
type of invasive prenatal procedure, study design, sample size of the study, study 
period and gestational age at assessing pregnancy outcome. 
 
Selection of studies for systematic review 
The selection of studies for the systematic review was based on identifying studies that 
provided results from large controlled studies. Firstly, we only included those studies 
reporting results on amniocentesis and CVS and excluded studies examining 
procedure-related complications following other prenatal diagnostic procedures. 
Secondly, we included those studies that provided data regarding risks of pregnancy 
loss not only from those that had an invasive procedure but also control pregnancies to 
allow for estimation of procedure-related risks. Thirdly, only those studies that reported 
results from at least 1,000 procedures were included to minimize biases from 
introduction of smaller case-studies. Lastly, we excluded those studies reporting data 
regarding preterm birth prior to 28 weeks and stillbirths but only those that included 
results relating to miscarriage, which was defined as pregnancy loss prior to 24 weeks’ 
gestation. 
 
The citations were examined by two independent reviewers (JB and RA) to produce a 
list of relevant studies to be included in the systematic review based on the MeSH 
terms and key words described above. We excluded studies that were duplicates, 
those that did not fit selection criteria after review of title and abstract and those that 
were either case-reports, letters, or review articles. The full-text of the remaining 
relevant manuscripts was retrieved in full-text to assess suitability for the systematic 
review. The reference lists of relevant articles and reviews were searched for additional 
reports and any inconsistencies were discussed to reach a consensus.  
 
Data collection and systematic review 
The data from each study included in the systematic review was extracted with regard 
to the type of procedure, study design, sample size of cases and controls, and 
miscarriage rate in each study group. Data for cases that had invasive procedure and 
controls were inputted in contingency tables and risk of miscarriage was estimated for 
each study. Summary statistics were calculated after taking into account the weighting 
for each study included in the systematic review. Procedure-related risk of miscarriage 
was estimated as a weighted risk difference from the summary statistics for cases and 
controls. The statistical software package StatsDirect version 3.1.11 (StatsDirect Ltd, 
Cheshire, UK) was used for data analysis. 
 
 
Results 
 
Data search results 
The electronic search from the databases yielded 2,465 potential citations of which 
2,431 were excluded as they were duplicates (n=486) or a review of the title or abstract 
did not meet the inclusion criteria (n=1616), leaving 34 studies for full-text review. After 
the full manuscript review, we included 10 studies for amniocentesis7-16 and 6 studies 
for CVS7,16,18-20, which were used to estimate the procedure-related risk of miscarriage. 
The study selection process is shown in the flow chart in Figure 1. 
 Amniocentesis group 
There were a total of 623 miscarriages from 64,901 amniocentesis procedures with a 
risk of pregnancy loss of 0.95% (95%CI: 0.70 to 1.24). In the control group, there were 
1,825 miscarriages in 299,979 pregnancies with a loss rate of 0.60% (95CI%: 0.47 to 
0.75). The weighted procedure-related risk of rate of miscarriage was 0.35% (95%CI: 
0.07 to 0.63) (Table 1).  
 
Chorionic villus sampling group 
There were a total of 327 miscarriages from 19,000 CVS procedures with a risk of 
pregnancy loss of 1.59% (95%CI: 0.74 to 2.76). In the control group, there were 1,524 
miscarriages in 202,706 pregnancies with a loss rate of 1.23% (95CI%: 0.74 to 1.86). 
The weighted procedure-related risk of miscarriage following CVS was 0.35% (95%CI: 
-0.31 to 1.00) (Table 2).  
 
 
Discussion 
The results of the systematic review demonstrate that the procedure-related risk of 
miscarriage from amniocentesis and CVS are lower than currently quoted in literature. 
The attributable risk for amniocentesis and CVS is similar, which is about 0.35% 
(95%CI: 0.07 to 0.63) and 0.35 (95% CI: -0.31 to 1.00), respectively.  
 
The strength of this study is a systematic search of published literature to identify 
manuscripts that reported results from large controlled studies and estimation of 
weighted summary statistics to calculate the procedure-related risk of miscarriage by 
taking into account the event rate and sample size in case and control groups. The 
limitation of such a systematic review study design is the inevitable introduction of 
biases introduced due to heterogeneity between studies and although such biases 
cannot be completely removed but mitigated to an extent by measures undertaken in 
this study such as inclusion of only controlled studies and those reporting results from 
experienced centres.  
 
The findings of this systematic review are consistent with results of recent studies 
which demonstrate that the risks of procedure-related loss are considerably lower than 
currently quoted and that undergoing an invasive procedure does not significantly 
increase this risk.6,7,19 In a recent nationwide population based study of 147,987 women 
with a singleton pregnancy including 5,072 who underwent CVS and 1,809 who 
underwent amniocentesis, the authors reported that the procedure-related risk of 
miscarriage at 21 days following CVS was -0.21% and that at 28 days following 
amniocentesis was 0.56%. The authors reported that there was no significant 
difference in the risk of miscarriage in those that had an amniocentesis or CVS 
compared to those that did not. 7 Similarly, a meta-analysis of large controlled studies 
reporting results from 324 losses in 42,176 women who underwent amniocentesis and 
207 losses in 8,899 women who underwent CVS stated that the procedure-related risk 
of miscarriage is about 0.1% and 0.2%, respectively.6 The results are also consistent 
with another large observational cohort study of 33,856 women including 2,396 that 
underwent a CVS which reported that there was no significant difference in the risk of 
miscarriage after adjusting for maternal and pregnancy characteristics in women who 
had a CVS compared to those that did not. This study highlighted the important fact 
that although the procedure-related risk of miscarriage associated with CVS could be 
derived by comparing pregnancy outcome in women undergoing the procedure with 
those that do not have an invasive test, such comparisons are likely to overestimate 
the risks in the CVS group because the same components of screening leading to 
increased risk for chromosomal defects and therefore the uptake of CVS, such as high 
fetal nuchal translucency (NT), reversed a-wave in the fetal ductus venosus and 
decreased serum pregnancy associated plasma protein-A (PAPP-A), are also 
associated with increased risk for miscarriage.19 Similar results were reported in a 
recent study by Wah et al., who estimated the risk of miscarriage in 1,906 CVS 
procedures and 7,634 controls and noted that the procedure-related risks was 0.15%.20 
Another recent study reported their results of a large cohort of women undergoing 
transabdominal and transvaginal CVS and reported that the procedure-related risks of 
miscarriage are 1.57% but this includes all operators – experienced and inexperienced. 
When the risk of miscarriage was assessed based on the level of expertise, the risk of 
miscarriage dropped from 2.24% for inexperienced operators to 0.42% for experienced 
operators.  
 
The results of this systematic review as well as those of recently published large 
population studies and meta-analysis demonstrate that the procedure-related risks of 
miscarriage following amniocentesis and CVS performed by Fetal Medicine experts in 
experienced centres is considerably lower than that currently quoted to women. It is 
important to provide women with accurate information when they consider options for 
prenatal diagnosis.  
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Figure Legends 
 
Figure 1. Flow chart demonstrating process of selection of studies included in the 
systematic review 
Table 1. Procedure-related risk of miscarriage in pregnancies undergoing amniocentesis calculated as a weighted risk difference (95% 
confidence interval) from miscarriage rate in controlled studies 
 
CI = Confidence Interval 
Author 
Amniocentesis group Control group 
Procedure-related loss 
% (95% CI) 
Study 
weight (%) Total 
Miscarriage rate 
n (%, 95% CI) 
Total 
Miscarriage rate 
n (%, 95% CI) 
Muller et al., 20028 3472 31 (0.89, 0.61 to 1.27) 47004 197 (0.42, 0.36 to 0.48) 0.47 (0.20 to 0.85) 10.83 
Eddleman et al., 20069 3096 31 (1.00, 0.68 to 1.42) 31907 300 (0.94, 0.84 to 1.05) 0.06 (-0.26 to 0.49) 10.36 
Kong et al., 200610 3468 39 (1.12, 0.80 to 1.53) 1125 13 (1.16, 0.62 to 1.97) -0.03 (-0.89 to 0.60) 6.90 
Towner et al., 2007111 15005 69 (0.46, 0.36 to 0.58) 17045 90 (0.53, 0.42 to 0.65) -0.07 (-0.22 to 0.09) 12.14 
Odibo et al., 200812 11695 113 (0.97, 0.80 to 1.16) 39594 335 (0.85, 0.76 to 0.94) 0.12 (-0.07 to 0.33) 11.85 
Pitukkijronnakorn et al., 201113 2990 11 (0.37, 0.18 to 0.66) 1495 3 (0.20, 0.04 to 0.59) 0.17 (-0.25 to 0.49) 10.87 
Corrado et al., 201214 2990 30 (1.00, 0.68 to 1.43) 487 4 (0.82, 0.22 to 2.09) 0.18 (-1.12 to 0.86) 5.63 
Theodora et al., 201515 12413 155 (1.25, 1.06 to 1.46) 6993  43 (0.61, 0.45 to 0.83) 0.63 (0.36 to 0.90) 11.30 
Wulff et al., 20167 1809 20 (1.11, 0.68 to 1.70) 147987 820 (0.55, 0.52 to 0.59) 0.55 (0.16 to 1.15) 9.16 
Bakker et al., 201716 7963 124 (1.56, 1.30 to1.85) 6342 20 (0.31, 0.19 to 0.49) 1.24 (0.95 to 1.56) 10.96 
Summary statistic 64901 623 (0.95, 0.70 to 1.24) 299979 1825 (0.60, 0.47 to 0.75) 0.35 (0.07 to 0.63) 100.00 
Table 2. Procedure-related risk of miscarriage in pregnancies undergoing chorionic villus sampling (CVS) calculated as a weighted risk 
difference (95% confidence interval) from miscarriage rate in controlled studies 
 
 
 
 
 
 
 
CI=Confidence Interval 
 
 
 
Author 
CVS group Control group 
Procedure-related loss 
% (95% CI) 
Study 
weight (%) Total 
Miscarriage rate 
n (%, 95% CI) 
Total 
Miscarriage rate 
n (%, 95% CI) 
Lau et al., 200517 1355 25 (1.85, 1.20 to 2.71) 1125 13 (1.16, 0.62 to 1.97) 0.69 (-0.30 to 1.69) 13.72 
Odibo et al., 200818 5148 138 (2.68, 2.26 to 3.16) 4803 161 (3.35, 2.86 to 3.90) -0.67 (-1.35 to -0.01) 16.03 
Akolekar et al., 201119 2396 44 (1.84, 1.34 to 2.46) 31460 360 (1.14, 1.03 to 1.27) 0.69 (0.21 to 1.32) 16.99 
Wulff et al., 20167 5072 17 (0.34, 0.20 to 0.54) 147987 820 (0.55, 0.52 to 0.59) -0.21 (-0.35 to -0.02) 19.08 
Wah et al., 201720 1906 16 (0.84, 0.48 to 1.36) 7687 53 (0.69, 0.52 to 0.90) 0.15 (-0.24 to 0.69) 17.70 
Bakker et al., 201716 3123 87 (2.79, 2.24 to 3.43) 9644 117 (1.21, 1.00 to 1.45) 1.57 (1.00 to 2.24) 16.48 
Summary statistic 19000 327 (1.59, 0.74 to 2.76) 202706 1524 (1.23, 0.74 to 1.86) 0.35 (-0.31 to 1.00) 100.00 
